Cargando…

Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy

PURPOSE OF REVIEW: Effective adjuvant treatment with immunotherapy and targeted therapy has significantly improved outcomes for patients with resectable locally advanced or metastatic melanoma, but a substantial proportion unfortunately relapse. Here, we review available data and explore evolving re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ng, Gary, Xu, Wen, Atkinson, Victoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Melanoma (DB Johnson, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474352/ https://www.ncbi.nlm.nih.gov/pubmed/35639333 http://dx.doi.org/10.1007/s11912-022-01288-y

Ejemplares similares

Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
por: Dixon-Douglas, Julia R., et al.
Publicado: (2022)

Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy
por: Bloemendal, Martine, et al.
Publicado: (2019)

A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis
por: Vreeland, Timothy J., et al.
Publicado: (2021)

Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study
por: Moncrieff, Marc D., et al.
Publicado: (2022)

Designing Traceability into Big Data Systems
por: McClatchey, Richard, et al.
Publicado: (2015)

In Sentinel Node-Positive Melanoma Patients, Does Omission of Completion Lymph Node Dissection Make More Intensive Follow-Up Necessary, and Does Adjuvant Systemic Therapy Permit Less Intensive Follow-Up?
por: Thompson, John F.
Publicado: (2021)

Outcome After Therapeutic Lymph Node Dissection in Patients with Unknown Primary Melanoma Site
por: Prens, Sebastiaan P., et al.
Publicado: (2011)

Improved Perioperative Seroma and Complication Rates Following the Application of a 2-Layer Negative Pressure Wound Therapy System After Inguinal Lymphadenectomy for Metastatic Cutaneous Melanoma
por: Moncrieff, Marc D., et al.
Publicado: (2020)

Use of S-100B to Evaluate Therapy Effects during Bevacizumab Induction Treatment in AJCC Stage III Melanoma
por: Kruijff, S., et al.
Publicado: (2011)

Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases
por: Lawless, Anna K., et al.
Publicado: (2022)

Sorting Through the Heterogeneity of Recurrent Melanoma
por: Jacobs, Lisa K., et al.
Publicado: (2008)

Survival and the Sentinel Lymph Node in Melanoma
por: Faries, Mark
Publicado: (2009)

Cutaneous Melanoma and Sentinel Lymph Node Biopsy
por: van Akkooi, A. C. J., et al.
Publicado: (2008)

Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
por: Rauwerdink, Daan Jan Willem, et al.
Publicado: (2020)

Quality of Life After Axillary or Groin Sentinel Lymph Node Biopsy, With or Without Completion Lymph Node Dissection, in Patients With Cutaneous Melanoma
por: de Vries, Mattijs, et al.
Publicado: (2009)

The basal position of nuclei is one pre-requisite for asymmetric cell divisions in the early mouse embryo
por: Ajduk, Anna, et al.
Publicado: (2014)

Isolated Tumor Cells and Long-Term Prognosis of Patients with Melanoma
por: van Akkooi, A. C. J., et al.
Publicado: (2008)

Who Is to Blame for False-Negative Sentinel Node Biopsies in Melanoma?
por: Sondak, Vernon K., et al.
Publicado: (2009)

Trends in Sentinel Lymph Node Biopsy Enactment for Cutaneous Melanoma
por: El Sharouni, Mary-Ann, et al.
Publicado: (2019)

Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
por: Thompson, John F., et al.
Publicado: (2014)

Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2016)

The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma
por: Wei, Xiaoting, et al.
Publicado: (2020)

The MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients—Results after 1 Year
por: Damude, Samantha, et al.
Publicado: (2016)

Molecular Characterization and Patient Outcome of Melanoma Nodal Metastases and an Unknown Primary Site
por: Gos, Aleksandra, et al.
Publicado: (2014)

Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites?
por: Wevers, K. P., et al.
Publicado: (2012)

Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients
por: Park, Tristen S., et al.
Publicado: (2017)

COVID-19 is Affecting the Presentation and Treatment of Melanoma Patients in the Northeastern United States
por: Davis, Catherine H., et al.
Publicado: (2021)

S-100B Concentrations Predict Disease-Free Survival in Stage III Melanoma Patients
por: Kruijff, S., et al.
Publicado: (2009)

Prognostic Significance of Sentinel Lymph Node Status in Thick Primary Melanomas (> 4 mm)
por: Holmberg, Carl-Jacob, et al.
Publicado: (2023)

The MelFo Study UK: Effects of a Reduced-Frequency, Stage-Adjusted Follow-Up Schedule for Cutaneous Melanoma 1B to 2C Patients After 3-Years
por: Moncrieff, Marc D., et al.
Publicado: (2020)

Impact of Shave Biopsy on Diagnosis and Management of Cutaneous Melanoma: A Systematic Review and Meta-Analysis
por: Ahmadi, Omid, et al.
Publicado: (2021)

The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma
por: Dieng, Mbathio, et al.
Publicado: (2022)

Risk Stratification of Sentinel Node Metastasis Disease Burden and Phenotype in Stage III Melanoma Patients
por: Hussain, Zahra, et al.
Publicado: (2022)

The MELFO Study: A Multicenter, Prospective, Randomized Clinical Trial on the Effects of a Reduced Stage-Adjusted Follow-Up Schedule on Cutaneous Melanoma IB–IIC Patients—Results After 3 Years
por: Deckers, Eric A., et al.
Publicado: (2019)

Detection of Melanoma Nodal Metastases; Differences in Detection Between Elderly and Younger Patients Do Not Affect Survival
por: Kruijff, S., et al.
Publicado: (2010)

Potential Cost-Effectiveness of US-Guided FNAC in Melanoma Patients as a Primary Procedure and in Follow-Up
por: van Akkooi, Alexander C. J., et al.
Publicado: (2009)

Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma
por: Belgrano, Valerio, et al.
Publicado: (2019)

Effectiveness of SPECT/CT Imaging for Sentinel Node Biopsy Staging of Primary Cutaneous Melanoma and Patient Outcomes
por: Moncrieff, Marc, et al.
Publicado: (2021)

Comments on Post-Publication Discussion of “Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma”
por: Cook, Robert W., et al.
Publicado: (2022)

20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters
por: Deroose, Jan P., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_8nl18tk7kdh6pmpkijr59vjdkr